Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OTIC

Otonomy (OTIC) Stock Price, News & Analysis

Otonomy logo

About Otonomy Stock (NASDAQ:OTIC)

Key Stats

Today's Range
$0.0085
$0.0085
50-Day Range
$0.01
$0.12
52-Week Range
$0.01
$2.54
Volume
N/A
Average Volume
937,525 shs
Market Capitalization
$582,479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

Otonomy, Inc.: Otonomy Provides Corporate Update
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Otonomy Provides Corporate Update
5 Investors Betting Big on Otonomy (OTIC) Stock
Why Is Otonomy (OTIC) Stock Up 97% Today?
See More Headlines

OTIC Stock Analysis - Frequently Asked Questions

Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19).

Based on aggregate information from My MarketBeat watchlists, some other companies that Otonomy investors own include Trevena (TRVN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/10/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Profitability

Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
67,780,000
Market Cap
$582,479.50
Optionable
Optionable
Beta
1.54

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:OTIC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners